GARCEAU ROGER 4

What Happened

• Roger Garceau, a director of Protara Therapeutics, received an award of 31,000 derivative shares on 2026-06-15. The transaction price is reported as $0.00, indicating an awarded grant rather than a market purchase or sale. This was reported on a Form 4 filed 2026-06-16.

Key Details

• Transaction type: Award/Grant (code A); derivative security.
• Transaction date: 2026-06-15; Form 4 filed: 2026-06-16 (filed within the typical 2-business-day window).
• Price: $0.00 per share (no cash paid by the insider).
• Shares subject to vesting: 31,000; vest in full on the first anniversary of the grant or upon a Change of Control, contingent on continued board service (footnote F1).
• Shares owned after the transaction: not specified in the filing.

Context

• This is a standard board compensation award (likely restricted stock or RSUs) and does not represent an open-market purchase or sale. Because the shares vest in the future, they are not immediately tradable and do not indicate an immediate personal liquidity event.